NR3C2 and type 2 diabetes mellitus: Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) that reduces the risk of CV outcomes and kidney disease progression in a broad range of patients with CKD and T2D.48 The FINEARTS-HF trial tested the hypothesis that finerenone (maximum dose of 20–40 mg o.d.), in addition to usual therapy, would reduce the rate of total worsening HF events and CV death among patients with HF and mildly reduced ejection fraction (EF) (HFmrEF) or HFpEF.